The Global Oligonucleotide Therapeutics Market was valued at USD 7.7 billion in 2025 and is estimated to grow at a CAGR of 23.4% to reach USD 72.1 billion by 2035.
The oligonucleotide therapeutics market is undergoing a significant structural transformation as nucleic acid-based drug modalities evolve from narrowly focused rare-disease treatments into a broader and more established therapeutic category across multiple clinical areas. Increasing scientific advancements in RNA-based medicine, improved delivery technologies, and growing clinical validation are collectively driving the expansion of this market. The integration of advanced conjugation chemistries has significantly improved drug stability, targeted delivery, and dosing convenience, supporting wider patient adoption. At the same time, the application of oligonucleotide therapies is extending beyond rare genetic disorders into more prevalent chronic and metabolic diseases, substantially broadening the commercial opportunity base. Regulatory approvals have increased steadily, reflecting rising confidence in the safety and efficacy of RNA-targeted treatments. Growing investment in biopharmaceutical research and development is accelerating pipeline expansion, while pharmaceutical companies are focusing on next-generation RNA platforms to enhance therapeutic precision and durability. These factors, combined with improved patient compliance through simplified administration formats and extended dosing intervals, are expected to sustain strong long-term growth across the global oligonucleotide therapeutics market.
In 2025, antisense oligonucleotides accounted for 39.9% share. This dominance is attributed to their well-established clinical utility and extensive application across multiple therapeutic areas. These single-stranded nucleic acid sequences function by binding to specific messenger RNA targets, enabling gene expression modulation through degradation or translation interference mechanisms. Continued advancements in molecular design and delivery systems are further strengthening their clinical relevance and commercial adoption.
The subcutaneous administration route represented 56.4% share in 2025. Its prominence is driven by its compatibility with modern RNA-based drugs that allow self-administration and reduced dependence on clinical settings. This route improves patient convenience, enhances treatment adherence, and reduces healthcare system burden, making it a preferred option for long-term therapeutic regimens. Expanding use of long-acting formulations continues to reinforce its dominant position.
North America Oligonucleotide Therapeutics Market accounted for 57.9% share in 2025, maintaining its leadership position due to strong biopharmaceutical innovation, advanced healthcare infrastructure, and favorable reimbursement frameworks. The region benefits from early adoption of RNA-based therapies and a well-established regulatory environment that supports accelerated drug approvals. High investment in rare disease research and strong commercial uptake of premium-priced therapies continue to support sustained market dominance across North America.
Major companies operating in the global oligonucleotide therapeutics market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, Biogen, Astellas Pharma, Novartis, AstraZeneca, Novo Nordisk, Sanofi, Arrowhead Pharmaceuticals, and NS Pharma. Companies operating in the oligonucleotide therapeutics market are strengthening their competitive position through continuous investment in RNA platform technologies, advanced drug delivery systems, and precision medicine approaches. Market participants are expanding clinical pipelines across multiple therapeutic areas while enhancing formulation strategies to improve stability, efficacy, and patient compliance. Strategic collaborations with biotechnology firms, research institutions, and academic organizations are accelerating innovation and shortening development timelines. Companies are also focusing on scalable manufacturing capabilities to support growing commercial demand and ensure consistent product quality.
This product will be delivered within 2-4 business days.
The oligonucleotide therapeutics market is undergoing a significant structural transformation as nucleic acid-based drug modalities evolve from narrowly focused rare-disease treatments into a broader and more established therapeutic category across multiple clinical areas. Increasing scientific advancements in RNA-based medicine, improved delivery technologies, and growing clinical validation are collectively driving the expansion of this market. The integration of advanced conjugation chemistries has significantly improved drug stability, targeted delivery, and dosing convenience, supporting wider patient adoption. At the same time, the application of oligonucleotide therapies is extending beyond rare genetic disorders into more prevalent chronic and metabolic diseases, substantially broadening the commercial opportunity base. Regulatory approvals have increased steadily, reflecting rising confidence in the safety and efficacy of RNA-targeted treatments. Growing investment in biopharmaceutical research and development is accelerating pipeline expansion, while pharmaceutical companies are focusing on next-generation RNA platforms to enhance therapeutic precision and durability. These factors, combined with improved patient compliance through simplified administration formats and extended dosing intervals, are expected to sustain strong long-term growth across the global oligonucleotide therapeutics market.
In 2025, antisense oligonucleotides accounted for 39.9% share. This dominance is attributed to their well-established clinical utility and extensive application across multiple therapeutic areas. These single-stranded nucleic acid sequences function by binding to specific messenger RNA targets, enabling gene expression modulation through degradation or translation interference mechanisms. Continued advancements in molecular design and delivery systems are further strengthening their clinical relevance and commercial adoption.
The subcutaneous administration route represented 56.4% share in 2025. Its prominence is driven by its compatibility with modern RNA-based drugs that allow self-administration and reduced dependence on clinical settings. This route improves patient convenience, enhances treatment adherence, and reduces healthcare system burden, making it a preferred option for long-term therapeutic regimens. Expanding use of long-acting formulations continues to reinforce its dominant position.
North America Oligonucleotide Therapeutics Market accounted for 57.9% share in 2025, maintaining its leadership position due to strong biopharmaceutical innovation, advanced healthcare infrastructure, and favorable reimbursement frameworks. The region benefits from early adoption of RNA-based therapies and a well-established regulatory environment that supports accelerated drug approvals. High investment in rare disease research and strong commercial uptake of premium-priced therapies continue to support sustained market dominance across North America.
Major companies operating in the global oligonucleotide therapeutics market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sarepta Therapeutics, Biogen, Astellas Pharma, Novartis, AstraZeneca, Novo Nordisk, Sanofi, Arrowhead Pharmaceuticals, and NS Pharma. Companies operating in the oligonucleotide therapeutics market are strengthening their competitive position through continuous investment in RNA platform technologies, advanced drug delivery systems, and precision medicine approaches. Market participants are expanding clinical pipelines across multiple therapeutic areas while enhancing formulation strategies to improve stability, efficacy, and patient compliance. Strategic collaborations with biotechnology firms, research institutions, and academic organizations are accelerating innovation and shortening development timelines. Companies are also focusing on scalable manufacturing capabilities to support growing commercial demand and ensure consistent product quality.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Molecule Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Indication, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Route of Administration, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
- Alnylam Pharmaceuticals
- Arrowhead Pharmaceuticals
- Astellas Pharma
- AstraZeneca
- Biogen
- Ionis Pharmaceuticals
- Novartis
- NS Pharma
- Novo Nordisk
- Sarepta Therapeutics
- Sanofi
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 152 |
| Published | June 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 7.7 Billion |
| Forecasted Market Value ( USD | $ 72.1 Billion |
| Compound Annual Growth Rate | 23.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
